Feed SURI
SU

Simplify Propel Opportunities ETF SURI AMEX · Financials · United States

$15.51 -0.21% -$0.03

Summary

Simplify Propel Opportunities ETF is an ETF - a fund traded on an exchange like a stock - run by Simplify. Positions inside: 38. The ten largest make up 83% of the fund.

Yearly costs
2.84%
Fund size
$70.1M
Positions
38
Dividend yield
17.54%
Running since
2023

What speaks for it

Nothing stands out in its favour.

What to watch

  • The ten largest positions make up 83% of the fund, so its result rests on a few names.
  • 55% of the fund is in one sector (Healthcare).
  • 93% of the fund is in one country (United States).
  • Costs of 2.84% a year are above the middle of comparable funds (0.45%).
  • In the last five years its price once dropped by 52% from its high.
  • A small fund with $70.1M under management; small funds get closed more often.
  • It trades little: only about $69.9K changes hands a day.

A fund has no Bulios Score and no Fair Price of its own - both are computed from the results of a single company. This page shows what is inside the fund and what it costs instead.

Price

Performance

1 month
-6.6%
3 months
-20%
This year
-6.8%
1 year
-7.4%
3 years
-19%
Avg. market cap
$3.19B
P/E
12.2x
Forward P/E
12.0x
P/S
0.2x
P/B
3.3x
P/FCF
2.8x
EV/EBITDA
6.5x
Dividend yield
3.23%
ROIC
-18.5%
ROE
-64.9%
Gross margin
-135.8%
Operating margin
-5,440.5%
Net margin
-5,175.6%
Payout ratio
39.3%
Net debt/EBITDA
1.9x
Beta
1.19

Weighted average of the 21 largest companies, which make up 63% of the fund. Banks and insurers are left out of the gross margin, the ROIC and the EBITDA figures.

What is inside?

Concentrated
  1. 1
    PA
    Plains GP Holdings, L.P. PAGP 32%
  2. 2
    SB
    Simplify Government Money Market ETF SBIL 15%
  3. 3 ACHIEVE LIFE SCIENCES INC USD 0.001 8.4%
  4. 4 Cash 6.2%
  5. 5
    DC
    Delcath Systems, Inc. DCTH 6.1%
  6. 6 ACHIEVE LIFE SCIENCES I WTS 30JUN30 4.6%
  7. 7
    CO
    Collegium Pharmaceutical, Inc. COLL 3.4%
  8. 8
    OB
    Orchestra BioMed Holdings, Inc. OBIO 2.7%
  9. 9
    MI
    Milestone Pharmaceuticals Inc. MIST 2.5%
  10. 10
    PH
    Phathom Pharmaceuticals, Inc. PHAT 2.2%

Positions in the fund: 38. The ten largest make up 83% of it.

Composition as of Nov 14, 2026.

Where is it spread?

One sector dominates

By sector

By country

By company size

By the company's market value: Mega cap from $200B, Large cap from $10B, Mid cap from $2B, Small cap from $300M, Micro cap below $300M. Counted from the companies that make up 63% of the fund.

Largest sector: Healthcare (55%). Largest country: United States (93%). Largest size group: Mid cap (55%).

What does it cost me?

Expensive
A year from $10,000
$284
Over 20 years
$11,200

From every $10,000 invested the fund takes $284 a year. You do not pay it separately - it is taken out of the fund's value. Over 20 years at 5% yearly growth that adds up to about $11,200.

How has it done?

Losing value
A year on average, 3 years
-6.7%
Deepest drop
-52%
Yearly volatility
23%

Average yearly decline over the last three years: 6.7%. Deepest drop in these years: 52% below the earlier high.

Does it pay dividends?

Yes, it pays out
Yield
17.54%
Payments a year
4
Last payment
$0.68

Over the last 12 months it paid $2.72 per share, which is 17.54% of today's price. The last payment was $0.68 on Sep 25, 2026.

Is it easy to buy and sell?

It trades little
Traded a day
$69.9K
Shares a day
4.5K

On an average day about $69.9K of the fund changes hands.

How expensive are the companies inside?

Rather cheap
P/E of the companies inside
12.2
Average Bulios Score
48 out of 100

Weight by Bulios Fair Price

On average the companies inside trade for 12.2 times their yearly profit. By Fair Price, 69% of the rated weight comes out as undervalued.

Counted from its largest companies (21), which make up 63% of the fund. Each company counts by its weight. We use the metrics, the Bulios Score and the Fair Price of the companies themselves.

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy